Actavis CEO: We may be big, but we don't want to be Big Pharma

Big Pharma or "growth pharma"? Actavis ($ACT) CEO Brent Saunders is aiming for the latter. Though his company is expected to rank among the industry's top 10 after closing its Allergan ($AGN) buy later this year, Saunders says Actavis won't act like a Big Pharma. What's the difference? He has some ideas. Report

Suggested Articles

The Pharma Lions shortlist for 2019 lives up to its name with just 31 entries making the cut. But it's still good news for the 12 drugmaker finalists.

Pharma companies filed suit Friday to block the new HHS rule that requires drugmakers to put list prices in TV ads.

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.